

[> 2009](#)

[> 2008](#)

[> 2007](#)

[> 2006](#)

2010



July 9, 2010

ExonHit's extraordinary shareholders' meeting on second notice



June 30, 2010

ExonHit's extraordinary shareholders' meeting



June 23, 2010

ExonHit updates its shareholders regarding the extraordinary shareholders' meeting about RedPath acquisition



June 18, 2010

ExonHit updates its shareholders on the acquisition of RedPath Integrated Pathology



June 14, 2010

ExonHit signs an exclusive agreement with Genmab for novel splice variant targets in breast cancer



June 9, 2010

ExonHit discloses the final terms of the acquisition of RedPath Integrated Pathology



May 26, 2010

ExonHit announces the holding of an extraordinary shareholders' meeting to approve the acquisition of RedPath Integrated Pathology





May 19, 2010

Change in ExonHit Management Board



May 10, 2010

ExonHit's 2010 combined ordinary and extraordinary shareholders' meeting



April 28, 2010

ExonHit's 2010 combined ordinary and extraordinary shareholders' meeting



April 26, 2010

ExonHit to acquire RedPath Integrated Pathology, Inc. and accelerate growth in molecular diagnostics



April 20, 2010

ExonHit confirms its intention to complete an external growth transaction in 2010



April 06, 2010

ExonHit receives "Innovative Company" accreditation from the French state innovation agency OSEO



March 31, 2010

ExonHit will participate to the Paris Smallcap Event on April 12 & 13



March 29, 2010

ExonHit presents new data on its Alzheimer's lead candidate at the International Geneva/Springfield Symposium



March 10, 2010

ExonHit Therapeutics reports 2009 annual results





March 8, 2010

ExonHit and bioMérieux decide not to pursue colon cancer program



March 3, 2010

ExonHit reports out-licensing of EHT/AGN 0001 by Allergan to Bristol-Myers Squibb



February 23, 2010

ExonHit announces the inclusion of proprietary lead compounds into Allergan collaboration



February 11, 2010

ExonHit chosen to join the European Innovative Medicines Initiative consortium on Alzheimer's disease

[Back to top](#)

2009



December 16, 2009

ExonHit announces the success of its capital increase



December 3, 2009

ExonHit launches first product in Alzheimer



November 5, 2009

ExonHit Therapeutics announces the appointment of its new Chief Financial Officer



November 2, 2009

ExonHit will participate in the MAPT study for the prevention of cognitive decline in old people



October 30, 2009

ExonHit presents new clinical advances on its Alzheimer's diagnostic and therapeutic programs



October 26, 2009

ExonHit strengthens its intellectual property position in the US



September 14, 2009

ExonHit presents promising first patient results for EHT 0202, its Alzheimer's candidate drug



September 8, 2009

ExonHit will participate to the Paris Midcap Event on September 21 & 22



July 30, 2009

ExonHit Therapeutics First half 2009 results



July 8, 2009

ExonHit raises EUR 1.45 million through the exercise of warrants



June 26, 2009

ExonHit announces the departure of its Chief Financial Officer



June 16, 2009

ExonHit announces last patient out for EHT 0202 Phase IIa study in Alzheimer



May 27, 2009

ExonHit and Institut Gustave Roussy announce the signing of a license agreement for novel breast cancer diagnostic assay.





May 19, 2009

ExonHit enters into a liquidity agreement.



May 6, 2009

ExonHit's 2009 Extraordinary Annual Meeting.



April 28, 2009

ExonHit's 2009 Ordinary Annual Meeting.



April 16, 2009

ExonHit will participate to the paris Smallcap event.



March 31, 2009

ExonHit expands neurological research activities to epilepsy.



March 16, 2009

ExonHit reports proof of concept in breast cancer diagnostic using its SpliceArray™ platform.



March 9, 2009

ExonHit Therapeutics shareholders equity strengthened by exercise of more than half of its convertible bonds.



March 4, 2009

ExonHit Therapeutics invested strongly in 2008 for pivotal 2009 results.



February 26, 2009

ExonHit Therapeutics reports advancements in the clinical development of EHT 0202, its phase II drug for Alzheimer's disease.





January 6,2009

ExonHit therapeutics expands strategic collaboration with allergan.

[Back to top](#)

2008



December 23,2008

ExonHit Therapeutics allocates free subscription warrants to all shareholders.



December 3,2008

ExonHit is honoured by the innovation trophy from the national institute of industrial property.



November 27,2008

ExonHit launches mouse genome SpliceArray™ for use in human disease modeling studies.



October 29,2008

ExonHit announces new scientific publications on the use of SpliceArrayT.



September 22,2008

ExonHit exclusive partnership with Xentech to provide molecular profiling services.



July 29,2008

ExonHit Therapeutics achievements for first half.



July 2,2008

ExonHit presents therapeutic and diagnostic programs for Alzheimer at ICAD.



June 4,2008

Loic Maurel joins ExonHit therapeutics to become CEO.



May 6,2008

ExonHit therapeutics launches the rat genome SpliceArrayT products.



April 30, 2008

Appointment of Frederic Desdouits on the supervisory board of ExonHit Therapeutics.



March 31,2008

ExonHit appoints a new Management Board.



March 25,2008

Exonhits EHT 0202 counters scopolamines detrimental.



March 5,2008

ExonHit therapeutics financial results 2007.



January 16,2008

ExonHit builds a new organization.



January 9,2008

ExonHit and bioMerieux amend their strategic partnership.

[Back to top](#)

2007



December 20, 2007

ExonHit initiates a Phase 2 clinical trial for EHT 0202 in Alzheimer's disease



November 8, 2007

ExonHit completes a prototype to detect Alzheimer's disease from blood



August 28, 2007

ExonHit strikes a milestone in its collaboration with Allergan



July 31, 2007

ExonHit Therapeutics - Achievements for first half 2007



June 7, 2007

In 2009 ExonHit aims to ask for market clearance in Europe for a blood diagnostic test for Alzheimer's disease



June 1st, 2007

ExonHit issues 400 000 new shares through the use of PACEO



May 11, 2007

Deborah Smeltzer appointed member of the supervisory board of ExonHit Therapeutics



April 17, 2007

ExonHit Therapeutics and bioMérieux present additional results in their breast cancer blood biomarkers program







March 15, 2007

ExonHit identifies a panel of genes to diagnose, from a blood, Alzheimer's disease







March 6, 2007

ExonHit 2006 financial results

- 
February 26, 2007
ExonHit issues 400 000 new shares through the use of PACEO
- 
February 20, 2007
ExonHit launches Human Genome SpliceArray™
- 
January 25, 2007
ExonHit raises 3.2 million euros through the exercise of warrants
- 
January 4, 2007
ExonHit Therapeutics and bioMerieux initiate a third diagnostic programme

[Back to top](#)

2006

- 
November 23, 2006
ExonHit Therapeutics - Clinical Therapeutic Programs
- 
November 8, 2006
Appointment of a new member of the Supervisory Board
- 
October 25, 2006
ExonHit success of the issuance of convertible bonds
- 
October 24, 2006


ExonHit presents preliminary characteristics of the issuance of convertible bonds

- 
October 19, 2006


ExonHit to start a research program on a blood diagnostic for Atherosclerosis

- 
September 20, 2006


ExonHit Therapeutics - solid first half 2006

- 
September 19, 2006


ExonHit extends strategic alliance with Allergan

- 
September 12, 2006


ExonHit appoints John Jaskowiak as Executive Business and marketing

- 
September 12, 2006

ExonHit - internet portal to market its microarrays

- 
September 7, 2006


ExonHit licences Merck rights to RNA splicing microarray patent

- 
September, 7 2006

ExonHit produces a new map for human genome expression

- 
July 25, 2006

First half 2006 revenues up by 46%

- 
july 5, 2006

ExonHit - Financial press release calendar



June 7, 2006

ExonHit - Emission of free warrants



June 16, 2006

ExonHit - Success of the secondary offering



June 14, 2006

Changes in the secondary offering



June 7, 2006

ExonHit - Secondary offering and free allocation of BSA



May 31, 2006

Agilent and ExonHit expand agreement



May 16, 2006

Alzheimer disease diagnostic patent



April 18, 2006

SpliceArrays on Affymetrix GeneChip platform



April 5, 2006

ExonHit announces the partial release of the lock-up for its principal shareholders



March 29, 2006

ExonHit bioMÃ©rieux breast cancer



February 21, 2006

2005 Financial Results



February 17, 2006

ExonHit therapeutics will begin continuous trading on Alternext on March 6, 2006



February 9, 2006

ExonHitâ SpliceArray service welcomes its 50th commercial project



January 5, 2006

ExonHit therapeutics strengthens its balance sheet

[Back to top](#)